CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
(Thomson Reuters ONE) -
In a release issued under the same headline earlier today by Apricus
Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the
subhead of the release, "2H 2016" should instead be "Q3 2016."
The corrected release follows:
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of
Tennessee Graduate School of Medicine
Vitaros U.S. NDA Re-Submission Remains on Schedule for Q3 2016
SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced it will host a Vitaros(®) and erectile
dysfunction ("ED") key opinion leader event on Monday, May 9(th), from 11:00
a.m. to 12:00 noon ET.
The meeting will feature a presentation by Edward D. Kim, M.D., Professor,
Division of Urology at The University of Tennessee Graduate School of Medicine,
Knoxville, TN. Dr. Kim will address the current status of treatment options in
the ED population, unmet patient need based on contraindications or suboptimal
response to currently available systemic treatments, provide an overview of the
clinical data for Vitaros, and discuss where a non-systemic, topical treatment
in the ED patient population may add value.
A live webcast with presentation slides and subsequent replay of the event will
be available at www.apricusbio.com. If you would like to ask a question during
the live Q&A, please submit your request via email tombeck(at)troutgroup.com.
Please log in approximately 5-10 minutes before the event to ensure a timely
connection. To participate by telephone, please dial (877) 841-3961 (Domestic)
or (201) 689-8589 (International). The conference ID number is 13633850. The
archived webcast will remain available for 30 days following the live
presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and
Canada and is being commercialized in several countries in Europe. In September
2015, Apricus in-licensed the U.S. development and commercialization rights for
Vitaros from Allergan. Apricus' marketing partners for Vitaros include
Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Recordati Ireland Ltd.
(Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals),
Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product
candidate, RayVa(TM), its product candidate for the treatment of the circulatory
disorder Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros(®) is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
mbeck(at)troutgroup.com
The Trout Group LLC
(646) 378-2933
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
[HUG#2009656]
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2016 - 20:43 Uhr
Sprache: Deutsch
News-ID 468479
Anzahl Zeichen: 3967
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
